<DOC>
	<DOCNO>NCT01274728</DOCNO>
	<brief_summary>This clinical evaluation study feasibility safety CE-marked paclitaxel-eluting balloon primary PCI patient STEMI . Drug elute balloon provide potential advantage deliver anti-proliferative drug , without disadvantage leave coronary stent , STEMI patient treat primary PCI .</brief_summary>
	<brief_title>PAclitaxel-eluting Balloon Primary PCI Amsterdam ; Pilot Study</brief_title>
	<detailed_description>Multiple randomize clinical trial pool analysis show improved clinical outcome primary PCI compare fibrinolytic therapy . Primary PCI STEMI result great patency infarct-related artery ( IRA ) low rate death , re-infarction , stroke compare fibrinolysis . The use coronary stent reduce need repeat revascularization patient treat primary PCI . However , set STEMI reduction target lesion revascularization ( TLR ) reduce re-infarction rate short term long-term mortality rate . This confirm large meta-analysis De Luca et al , use 13 randomized trial involve 6922 patient . In study evaluate DES versus BMS STEMI mortality rate similar patient treat BMS DES . Although TLR rate reduce use DES , concern long-term delay arterial healing produce Cypher DES Taxus DES associate risk late stent thrombosis . Anti-proliferative drug DES use prevent neointimal hyperplasia also prevent formation epithelial surface inner side stent cause possible stent malapposition potentionally late stent thrombosis . A new approach treatment STEMI available development drug elute balloon . These DEB use without additional stent placement . Potential advantage compare DES homogeneous drug distribution , short lasting exposure high local drug dose . Moreover , additional stent need , might reduce need long term aggressive anti-platelet therapy order prevent acute , late late stent thrombosis . In short , DEB provide potential advantage deliver anti-proliferative drug , without disadvantage leave coronary stent , STEMI patient treat primary PCI . The use DEB already test treatment de novo coronary lesion in-stent restenosis show feasible safe.In clinical evaluation use CE-marked Paclitaxel-eluting balloon provisional stenting STEMI evaluate top current high standard therapy .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Acute myocardial infarction eligible primary PCI : 20 min chestpain least 1 mm STelevation least two contiguous lead , new leave bundle branch block true posterior myocardial infarction reperfusion expect feasible within 12 hour onset complaint Infarct relate artery eligible PPCI include stent implantation . Diameter IRA ≥ 2.5 mm , ≤ 4 mm . Infarction cause de novo lesion native coronary artery Age &lt; 18 Reperfusion feasible within 12 hour onset complaint Failed thrombolysis Infarct related artery unsuitable PCI Subacute stent thrombosis STEMI cause instent restenosis Infarct related vessel / target vessel SVG LIMA Contraindication resistance bivalirudin , fondaparinux , aspirin , clopidogrel and/or prasugrel . Participation another clinical study , interfere protocol Cardiogenic shock prior inclusion Uncertain neurological outcome e.g . resuscitation Intubation/ventilation Known intracranial disease ( mass , aneurysm , AVM , hemorrhagic CVA , ischemic CVA/TIA &lt; 6 month prior inclusion ischemic CVA permanent neurological deficit ) Gastrointestinal / urinary tract bleed &lt; 2 month prior inclusion Refusal receive blood transfusion Platelet number &lt; 100.000 x 10^9/L Planned major surgery within 6 week Stent implantation &lt; 1 month prior inclusion Expected mortality cause within next 12 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Acute myocardial infarction</keyword>
	<keyword>Primary percutaneous coronary intervention</keyword>
	<keyword>Drug-eluting balloon</keyword>
	<keyword>Bivalirudin</keyword>
</DOC>